Matilde Dela Cruz
Payments from drug & device makers
Across 298 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$739
- Amgen$504
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$361
- GSK$325
- Lilly USA, LLC$284
- Novo Nordisk$272
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $739 |
| Amgen | 29 | $504 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $361 |
| GSK | 20 | $325 |
| Lilly USA, LLC | 18 | $284 |
| Novo Nordisk | 21 | $272 |
| Exact Sciences | 16 | $232 |
| Indivior Inc. | 8 | $197 |
| AstraZeneca | 11 | $181 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Sanofi-aventis U.S. LLC | 8 | $152 |
| Merck | 7 | $136 |
| Amarin Pharma, Inc. | 7 | $131 |
| Mylan Specialty L.p. | 8 | $126 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Neurocrine Biosciences, Inc. | 4 | $81 |
| Medtronic | 3 | $72 |
| Boehringer Ingelheim | 4 | $67 |
| Bayer | 4 | $64 |
| Scilex Pharmaceuticals Inc. | 4 | $60 |
| Novartis | 4 | $59 |
| Braeburn Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Pfizer | 2 | $36 |
| Ardelyx, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $34 |
| Antares Pharma, Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $24 |
| Lundbeck LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Averitas Pharma Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
How this compares
$4,769 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $66,602 |
| TrulicityDulaglutide | 53 | $60,638 |
| MounjaroTirzepatide | 46 | $49,529 |
| FarxigaDapagliflozin Propanediol | 63 | $43,765 |
| EliquisApixaban | 46 | $39,249 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $38,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $34,930 |
| JardianceEmpagliflozin | 42 | $27,656 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $24,510 |
| LinzessLinaclotide | 18 | $18,461 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $17,719 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,776 |
| VascepaIcosapent Ethyl | 24 | $9,524 |
| EntrestoSacubitril/Valsartan | 12 | $7,671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $7,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $284 | $110,16799 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $181 | $68,275100 claims |
| Novo NordiskOzempic | $272 | $66,60249 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $67 | $41,43265 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $325 | $40,30856 claims |
| PfizerEliquis | $36 | $39,24946 claims |
| AbbVieLinzess, Synthroid | $739 | $19,55330 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $152 | $17,71915 claims |
| NovartisEntresto | $59 | $7,67112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Boaz
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.